Experience

Ganymede

• United States
• Software Development
• 1 - 100 Employee

• Founding Scientist

  • May 2022 - Present



Nucleate

• United States
• Biotechnology Research
• 100 - 200 Employee

• Director of Strategy

  • Aug 2021 - May 2022

  • Lead a team to identify and recruit future bio-entrepreneurs working on highly promising and commercializable research for our flagship initiative “Activator” start-up educational program. • Map out the extensive NYC biotech ecosystem and build collaborative relationships across 10+ biomedical research institutions and business schools. • Establish partnerships with academic, non-profit, and industry advisors to mentor teams and facilitate successful biotech formation. • Find… Show more • Lead a team to identify and recruit future bio-entrepreneurs working on highly promising and commercializable research for our flagship initiative “Activator” start-up educational program. • Map out the extensive NYC biotech ecosystem and build collaborative relationships across 10+ biomedical research institutions and business schools. • Establish partnerships with academic, non-profit, and industry advisors to mentor teams and facilitate successful biotech formation. • Find sponsorship opportunities – both monetary and in-kind – to meet fundraising and marketing targets created in cooperation with the finance and communications teams. Show less • Lead a team to identify and recruit future bio-entrepreneurs working on highly promising and commercializable research for our flagship initiative “Activator” start-up educational program. • Map out the extensive NYC biotech ecosystem and build collaborative relationships across 10+ biomedical research institutions and business schools. • Establish partnerships with academic, non-profit, and industry advisors to mentor teams and facilitate successful biotech formation. • Find… Show more • Lead a team to identify and recruit future bio-entrepreneurs working on highly promising and commercializable research for our flagship initiative “Activator” start-up educational program. • Map out the extensive NYC biotech ecosystem and build collaborative relationships across 10+ biomedical research institutions and business schools. • Establish partnerships with academic, non-profit, and industry advisors to mentor teams and facilitate successful biotech formation. • Find sponsorship opportunities – both monetary and in-kind – to meet fundraising and marketing targets created in cooperation with the finance and communications teams. Show less



Columbia University Graduate School of Arts and Sciences

• United States
• Higher Education
• 1 - 100 Employee

• Graduate Student, Biomedical Engineering

  • Aug 2015 - May 2022

  • Created a novel organ-on-a-chip microfluidic platform (InterOrgan™) designed specifically for chemotherapeutic drug screening and capable of sustaining multiple bioengineered human tissues for at least 4 weeks of culture; • Repurposed the InterOrgan™ platform to recapitulate and subsequently study for the first time targeted, multi-tissue metastasis in a human in vitro model, mimicking the metastatic progression observed in in vivo mouse xenotransplants; • Designed osteosarcoma… Show more • Created a novel organ-on-a-chip microfluidic platform (InterOrgan™) designed specifically for chemotherapeutic drug screening and capable of sustaining multiple bioengineered human tissues for at least 4 weeks of culture; • Repurposed the InterOrgan™ platform to recapitulate and subsequently study for the first time targeted, multi-tissue metastasis in a human in vitro model, mimicking the metastatic progression observed in in vivo mouse xenotransplants; • Designed osteosarcoma and Ewing sarcoma GFP-luciferase reporter cell lines that were then bioengineered into physiologically biomimetic human bone tumor tissues. These were adapted along with bioengineered cardiac tissues into our InterOrgan™ platform, and used for simultaneous anti-tumor drug efficacy and cardiotoxicity studies according to clinical trial treatment regimens; • Orchestrated and published successful, large scale, comprehensive validation studies of our bioengineered bone tumor tissues with the independent labs of Dr. Ivan Rusyn (Texas A&M) and Dr. Murat Cirit (M.I.T.). Relevant data from these studies is available through a database generated in collaboration with the Drug Discovery Institute (University of Pittsburgh); • Assisted Dr. Manuela Raimondi’s lab (Politecnico di Milano) on two separate projects to elucidate the effects that biophysical stimuli have on the development of drug resistance in cancer; • Established new collaborations with clinicians Dr. Hanina Hibshoosh (HICCC, Columbia University) and Dr. Srikanth Ambati (MSKCC) to generate patient-derived, bioengineered cancer tissues (breast cancer organoids and primary bone tumors respectively) • Developed successful grants in excess of $1 million, including a highly competitive RO1 through the NCI • Published a review paper on the tissue engineering approaches used to model healthy and malignant bone marrow (A.D.D.R., Impact 15.5). • Established and implemented internal SOPs and research budgets, recruited/trained new staff Show less • Created a novel organ-on-a-chip microfluidic platform (InterOrgan™) designed specifically for chemotherapeutic drug screening and capable of sustaining multiple bioengineered human tissues for at least 4 weeks of culture; • Repurposed the InterOrgan™ platform to recapitulate and subsequently study for the first time targeted, multi-tissue metastasis in a human in vitro model, mimicking the metastatic progression observed in in vivo mouse xenotransplants; • Designed osteosarcoma… Show more • Created a novel organ-on-a-chip microfluidic platform (InterOrgan™) designed specifically for chemotherapeutic drug screening and capable of sustaining multiple bioengineered human tissues for at least 4 weeks of culture; • Repurposed the InterOrgan™ platform to recapitulate and subsequently study for the first time targeted, multi-tissue metastasis in a human in vitro model, mimicking the metastatic progression observed in in vivo mouse xenotransplants; • Designed osteosarcoma and Ewing sarcoma GFP-luciferase reporter cell lines that were then bioengineered into physiologically biomimetic human bone tumor tissues. These were adapted along with bioengineered cardiac tissues into our InterOrgan™ platform, and used for simultaneous anti-tumor drug efficacy and cardiotoxicity studies according to clinical trial treatment regimens; • Orchestrated and published successful, large scale, comprehensive validation studies of our bioengineered bone tumor tissues with the independent labs of Dr. Ivan Rusyn (Texas A&M) and Dr. Murat Cirit (M.I.T.). Relevant data from these studies is available through a database generated in collaboration with the Drug Discovery Institute (University of Pittsburgh); • Assisted Dr. Manuela Raimondi’s lab (Politecnico di Milano) on two separate projects to elucidate the effects that biophysical stimuli have on the development of drug resistance in cancer; • Established new collaborations with clinicians Dr. Hanina Hibshoosh (HICCC, Columbia University) and Dr. Srikanth Ambati (MSKCC) to generate patient-derived, bioengineered cancer tissues (breast cancer organoids and primary bone tumors respectively) • Developed successful grants in excess of $1 million, including a highly competitive RO1 through the NCI • Published a review paper on the tissue engineering approaches used to model healthy and malignant bone marrow (A.D.D.R., Impact 15.5). • Established and implemented internal SOPs and research budgets, recruited/trained new staff Show less



Memorial Sloan Kettering Cancer Center

• United States
• Hospitals and Health Care
• 700 & Above Employee

• Founding Member at The Center for Epigenetic Research - Research Technician

  • Jul 2014 - Aug 2015

  • Established an automated chromatin immunoprecipitation and sequencing platform for the Leukemia Center core facility operated by Dr. Scott A. Armstrong, as well as implemented whole genome bisulfite sequencing and chromatin accessibility assays • Due to the remarkable success of the initial core facility within the Leukemia Center, we quickly grew the operation into The Center for Epigenetic Research • Co-authored numerous publications featured in a variety of journals… Show more • Established an automated chromatin immunoprecipitation and sequencing platform for the Leukemia Center core facility operated by Dr. Scott A. Armstrong, as well as implemented whole genome bisulfite sequencing and chromatin accessibility assays • Due to the remarkable success of the initial core facility within the Leukemia Center, we quickly grew the operation into The Center for Epigenetic Research • Co-authored numerous publications featured in a variety of journals, including two in Nature Medicine • Performed alignments of sequencing data using Bowtie2 and analysis including peak calling using a combination of Unix, Python, and R scripts • Trained and managed new employees, and generated novel successful collaborations with researchers throughout the Human Oncology and Pathogenesis Program initially, and subsequently throughout the MSKCC network as well as other institutions such as Weill Cornell Medical Center, Rockefeller University, Dana Farber Cancer Institute, and St. Jude Children's Research Hospital. • Assisted in developing Filemaker databases in order to track all experiments, antibodies, and reagents • Assisted with pre-clinical drug trials in mouse leukemia xenotransplants and subsequent tissue isolation and analysis using flow cytometry and FlowJo

• Research Technician

  • Jul 2013 - Aug 2015



Cornell University

• United States
• Higher Education
• 700 & Above Employee

• Honors Thesis

  • Jan 2012 - May 2013

  • Completed an honors research project in the laboratory of Dr. Joseph E. Peters analyzing the functional role of the interaction between the transposon protein TnsE of the highly specific Tn7 transposon and SeqA, a negative modulator of initiation of DNA replication, in an E. coli model system • Additionally studied the functional role of the interaction between TnsE and several proteins that co-occur with SeqA in dam resident genomes - MetJ, MatP, YfbV, and MutH. • Completed an honors research project in the laboratory of Dr. Joseph E. Peters analyzing the functional role of the interaction between the transposon protein TnsE of the highly specific Tn7 transposon and SeqA, a negative modulator of initiation of DNA replication, in an E. coli model system • Additionally studied the functional role of the interaction between TnsE and several proteins that co-occur with SeqA in dam resident genomes - MetJ, MatP, YfbV, and MutH.